15 research outputs found
KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer
Background: Lung cancer is one of the most lethal cancers. It is mainly classified into 2 groups: non-small cell lung can-cer (NSCLC) and small cell lung cancer (SCLC). Extrapul-monary small cell carcinomas (EPSCC) are very rare. The Ras oncogene controls most of the cellular functions in the cell. Overall, 21.6% of human cancers contain a Kirsten Ras (KRAS) mutation. SCLC and EPSCC have several similar features but their clinical course is different.Aims: We investigated the KRAS mutation status in SCLC and EPSCC.Study design: Mutation research.Methods: Thirty-seven SCLC and 15 EPSCC patients were included in the study. The pathological diagnoses were confirmed by a second pathologist. KRAS analysis was performed in our medical genetic department. DNA isola-tion was performed with primary tumor tissue using the QIAamp DNA FFPE Tissue kit (Qiagen; Hilden, Germany) in all patients. The therascreen KRAS Pyro Kit 24 V1 (Qia-gen; Hilden, Germany) was used for KRAS analyses. Results: Thirty-four (91.9%) of the SCLC patients were male, while 11 (73.3%) of the EPSCC l patients were fe-male. SCLC was more common in males, and EPSCC in females (p=0.001). A KRAS mutation was found in 6 (16.2%) if SCLC patients. The most common mutation was Q61R (CAA>CGA). Among the 15 EPSCC patients, 2 had a KRAS mutation (13.3%). When KRAS mutant and wild type patients were compared in the SCLC group, no differ-ence was found for overall survival (p=0.6).Conclusion: In previous studies, the incidence of KRAS mutation in SCLC was 1-3%; however, it was 16.2% in our study. Therefore, there may be ethnic and geographical differences in the KRAS mutations of SCLC. As a result, KRAS mutation should not be excluded in SCL
Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status
Conclusions Metronomic vinorelbine had an acceptable efficacy and safety profile in elderly patients with multiple comorbidities who had been diagnosed with advanced nsclc. Metronomic vinorelbine could be a treatment option for elderly patients with poor performance status who are unfit for platinum-based chemotherapy and intravenous single-agent chemotherapy, and who are not candidates for combination modalities
HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (BMC Cancer, (2023), 23, 1, (136), 10.1186/s12885-023-10609-8)
Following publication of the original article [1], the authors reported an error in the author name of Enes Erul
KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer
Background: Lung cancer is one of the most lethal cancers.
It is mainly classified into 2 groups: non-small cell lung cancer
(NSCLC) and small cell lung cancer (SCLC). Extrapulmonary
small cell carcinomas (EPSCC) are very rare. The
Ras oncogene controls most of the cellular functions in the
cell. Overall, 21.6% of human cancers contain a Kirsten Ras
(KRAS) mutation. SCLC and EPSCC have several similar
features but their clinical course is different.
Aims: We investigated the KRAS mutation status in SCLC
and EPSCC.
Study design: Mutation research.
Methods: Thirty-seven SCLC and 15 EPSCC patients were
included in the study. The pathological diagnoses were
confirmed by a second pathologist. KRAS analysis was
performed in our medical genetic department. DNA isolation
was performed with primary tumor tissue using the
QIAamp DNA FFPE Tissue kit (Qiagen; Hilden, Germany)
in all patients. The therascreen KRAS Pyro Kit 24 V1 (Qiagen;
Hilden, Germany) was used for KRAS analyses.
Results: Thirty-four (91.9%) of the SCLC patients were
male, while 11 (73.3%) of the EPSCC l patients were female.
SCLC was more common in males, and EPSCC
in females (p=0.001). A KRAS mutation was found in 6
(16.2%) if SCLC patients. The most common mutation was
Q61R (CAA>CGA). Among the 15 EPSCC patients, 2 had
a KRAS mutation (13.3%). When KRAS mutant and wild
type patients were compared in the SCLC group, no difference
was found for overall survival (p=0.6).
Conclusion: In previous studies, the incidence of KRAS
mutation in SCLC was 1-3%; however, it was 16.2% in
our study. Therefore, there may be ethnic and geographical
differences in the KRAS mutations of SCLC. As a result,
KRAS mutation should not be excluded in SCLC
Value of MRI apparent diffusion coefficient for assessment of response to sorafenib in hepatocellular carcinoma
Conclusion: Advanced HCC patients with a favorable response to sorafenib had a significant increase in ADC value at the first radiological evaluation. The predictive and prognostic role of ADC for overall survival is still unknown and further research is needed to investigate any possible association
K-RAS and N-RAS mutations in testicular germ cell tumors
Testicular cancer is a relatively rare tumor type, accounting for approximately 1% of all cancers in men. However, among men aged between 15 and 40 years, testicular cancer is the most commonly diagnosed malignancy. Testicular germ cell tumors (TGCTs) are classified as seminoma and non-seminoma. The RAS oncogene controls several cellular functions, including cell proliferation, apoptosis, migration, and differentiation. Thus, RAS signaling is important for normal germ cell development. Mutations of the Kirsten RAS (K-RAS) gene are present in over 20% of all cancers. RAS gene mutations have also been reported in TGCTs. We investigated K-RAS and N-RAS mutations in seminoma and non-seminoma TGCT patients. A total of 24 (55%) pure seminoma cases and 19 (45%) non-seminoma cases were included in the study. K-RAS and N-RAS analyses were performed in our molecular pathology laboratory, using K-RAS and N-RAS Pyro Kit 24 V1 (Qiagen). In total, a RAS mutation was present in 12 patients (27%): 7 seminoma (29%) and 5 non-seminoma cases (26%) [p = 0.55]. AK-RAS mutation was present in 4 pure seminoma tumors (16%) and 3 non-seminoma tumors (15%) [p = 0.63], and an N-RAS mutation was observed in 4 seminoma tumors (16%) and 3 non-seminoma tumors (15%) [p = 0.63]. Both, K-RAS and N-RAS mutations were present in two patients: One with seminoma tumor and the other with non-seminoma tumor. To date, no approved targeted therapy is available for the treatment of TGCTs. The analysis of K-RAS and N-RAS mutations in these tumors may provide more treatment options, especially in platinum-resistant tumors
The effect of the gastrectomy on survival in patients with metastatic gastric cancer: a study of ASMO
Aim: To investigate the role of surgical resection of primary tumor on overall survival (OS) in advanced gastric cancer patients at the time of diagnosis. Patients & methods: The survival rates of metastatic gastric cancer patients whose gastric primary tumor was resected at time of diagnosis were compared with metastatic gastric cancer patients whose primary tumor was nonresected. Results: The median progression-free survival and OS in operated and nonoperated group were 10 versus 6, 14 versus 9 months, respectively (p < 0.001). In multivariate analysis, gastric resection of primary tumor, Eastern Cooperative Oncology Group performance status, second-line chemotherapy had a significant effect on OS (hazard ratio [HR]: 0.52 [95% CI: 0.38-0.71], HR: 0.57 [95% CI: 0.42-0.78], HR: 1.48 [1.09-2.01]; p <= 0.001, p = 0.001 and p = 0.012, respectively). Conclusion: Subpopulations of patients with metastatic gastric cancer might benefit from surgical removal of primary tumor